Opko Health Inc. Watch

from 10-Q 4 pages Neither This Debt Instrument Nor the Notes Issued in Connection Herewith Have Been Registered Under the Securities Act, or Any Applicable State Securities Laws. Such Securities Have Been Acquired for Investment Purposes and May Not Be Offered for Sale, Sold, Delivered After Sale, Transferred, Pledged or Hypothecated in the Absence of an Effective Registration Statement Filed by the Issuer (As Defined Below) With the U.S. Securities and Exchange Commission Covering Such Securities Under the Securities Act or an Opinion of Counsel Satisfactory to the Issuer That Such Registration Is Not Required

from 10-Q 5 pages Note Purchase Agreement Dated as of July 17, 2024 by and Among Opko Health, Inc., as Issuer, the Guarantors From Time to Time Party Hereto, the Various Purchasers From Time to Time Party Hereto, Hcr Injection Spv, LLC, as Agent

from 8-K 5 pages Convertible Note Purchase Agreement

from 8-K 2 pages Opko Health, Inc. 3.75% Convertible Senior Notes Due 2029 Purchase Agreement

from 10-Q 48 pages License and Research Collaboration Agreement

from 10-K 12 pages This Amended and Restated 5% Convertible Promissory Note and the Securities Issuable Upon Conversion Hereof Have Not Been Registered Under the Securities Act of 1933, as Amended (The “Securities Act”), or Any State Securities Laws, in Reliance Upon an Exemption From Registration Under the Securities Act, And, Accordingly, May Not Be Offered, Sold, Mortgaged, Pledged, Hypothecated, or Otherwise Transferred Except Pursuant to an Effective Registration Statement Under the Securities Act or Pursuant to an Available Exemption From, or in a Transaction Not Subject To, the Registration Requirements of the Securities Act and Otherwise in Compliance With Applicable State Securities Laws

from 8-K 10 pages Severance Agreement and General Release

from 8-K 24 pages Corporate Integrity Agreement Between the Office of Inspector General of the Department of Health and Human Services and Opko Health, Inc. and Bioreference Health, LLC

from 8-K 22 pages Settlement Agreement

from 8-K 4 pages Material contract

from 8-K 4 pages Material contract

from 8-K 13 pages Lock-Up and Voting Agreement

from 8-K 23 pages Shareholder Agreement

from 10-Q 42 pages Exclusive License Agreement by and Between Opko Health, Inc. and Camp4 Therapeutics Corporation Entered Into as of July 6, 2021

from 10-Q 59 pages License Agreement by and Among Eirgen Pharma Limited and Nicoya Macau Limited June 17, 2021

from 10-Q 68 pages Asset Purchase Agreement Among Eirgen Pharma Limited, Horizon Therapeutics Ireland Dac and Opko Health, Inc. (Solely for the Purposes of Sections 2.1, 8.3 and 11.16) Dated as of June 16, 2021

from 8-K 11 pages Exchange Agreement

from 10-Q 104 pages Amended and Restated Development and Commercialization License Agreement

from 10-Q 5 pages Amendment to Development and License Agreement

from 10-K 8 pages Article 1 Purchase and Sale of Common Stock